Medical Oncologist
Medicines
How much does abemaciclib actually help? The numbers explained
After surgery for high-risk early breast cancer, abemaciclib reduced recurrences by roughly seven to eight in every hundred people at around five years. In advanced cancer it kept the cancer controlled for longer. This page explains, in general and simplified terms, what the trials found, how to read the numbers and why your benefit may differ.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How much does abemaciclib actually help?
- Four ideas that make trial results clearer
- Key trials, in simplified terms
- The vocabulary, in plain language
- Honest realities about the numbers
- Why your benefit may differ from the average
- Balancing benefit against side effects and cost
- Asking your oncologist about numbers
- What people assume about abemaciclib's benefit
- Common questions about abemaciclib's benefit
The short answer
How much does abemaciclib actually help?
The benefit of abemaciclib depends on where it is used. After surgery for high-risk hormone receptor positive, HER2-negative early breast cancer, the monarchE trial compared two years of abemaciclib plus hormone therapy with hormone therapy alone. At around five years, roughly eighty-four in every hundred people taking abemaciclib were alive without the cancer returning or a new invasive cancer, compared with roughly seventy-six in every hundred on hormone therapy alone. Put simply, about seven or eight fewer people in every hundred had a recurrence or new invasive cancer by that point. The reduction in cancer returning in distant parts of the body was similar in size, and the gap has continued to widen during follow-up after the tablets stopped. In advanced breast cancer, abemaciclib with an aromatase inhibitor as first treatment roughly doubled the middle, or median, time before the cancer grew, from a little over a year to more than two years in the MONARCH three trial. Given with fulvestrant after earlier hormone therapy in the MONARCH two trial, it lengthened the median time before growth by around seven months and improved median overall survival by around nine to ten months. These are averages from trials. Some people benefit far more and some less, and the numbers that matter most are the ones your oncologist estimates for your own cancer.
After surgery
Abemaciclib lowers the chance of the cancer coming back. People at higher risk tend to gain more in absolute terms.
In advanced cancer
It keeps the cancer controlled for longer, and in one major trial it also helped people live longer.
Averages are not predictions
Trial results describe groups, not what will happen to any one person.
This page gives general information only. Figures are rounded and simplified from published trials. Your oncologist can explain what they mean for you.Understanding the numbers
Four ideas that make trial results clearer
A few simple concepts help you read benefit figures without being misled.
Absolute difference
How many fewer people out of a hundred had an event. This is usually the most useful number for decisions.
Relative reduction
The percentage by which risk falls. It can sound large even when the absolute difference is small.
Always ask for both.Median
The middle value: half of people did better and half did worse than this time.
Follow-up time
Early results can change as trials continue. Longer follow-up gives a clearer picture.
Questions to ask
- What is my baseline risk?
- How many fewer recurrences in a hundred?
- What are the costs in side effects?
The main trials
Key trials, in simplified terms
Trial and setting
Main finding, simplified
monarchE, after surgery
About seven to eight fewer recurrences per hundred at around five years
MONARCH three, first treatment for advanced cancer
Median time before growth roughly doubled
MONARCH two, after earlier hormone therapy
Longer control and longer median survival
MONARCH one, after chemotherapy
Some cancers shrank with abemaciclib alone
Dose reduction analyses
Benefit appeared to hold on lower doses
Words you will hear
The vocabulary, in plain language
- Invasive disease-free survival
- Time alive without the cancer returning or a new invasive cancer.
- Distant relapse-free survival
- Time without cancer spreading to other parts of the body.
- Progression-free survival
- Time without advanced cancer growing or spreading.
- Overall survival
- Time people live, whatever the cause.
- Hazard ratio
- A statistic comparing the rate of events between two groups over time.
- Statistical significance
- A test of whether a difference is unlikely to be due to chance alone.
Being straight with you
Honest realities about the numbers
Numbers can reassure or disappoint. They are most useful when you understand their limits.
Most people did well either way
After surgery, most people in both groups stayed free of recurrence. Abemaciclib shifted the odds for some, not all.
Survival results take time
In early breast cancer, effects on overall survival take many years to become clear. Ask about the latest updates.
Not every trial showed longer life
In MONARCH three, the survival difference favoured abemaciclib but did not meet the strict statistical test.
What this page cannot tell you
It cannot calculate your personal benefit. Your oncologist can use your pathology and health to estimate it.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Your own benefit
Why your benefit may differ from the average
Trial averages are a starting point. Several things shift how much any one person gains.
Starting risk
A person with many affected lymph nodes starts with a higher risk, so the same relative reduction prevents more recurrences.
Staying on treatment
Taking both abemaciclib and hormone therapy regularly matters. Dose reductions are better than stopping.
Other health conditions
Serious illnesses unrelated to cancer can affect how much a cancer treatment adds to life expectancy.
Cancer biology
Grade, growth rate and response to earlier treatment all influence risk and potential benefit.
Weighing it up
Balancing benefit against side effects and cost
A good decision puts benefit, burden and your own priorities side by side.
Side effects
Loose motions, tiredness and frequent tests are the main burdens, especially early on.
Cost and practicality
A long course of a targeted medicine is a significant expense for many families in India.
What matters to you
Some people value any reduction in risk; others weigh quality of life more heavily. Both views are valid.
In the clinic
Asking your oncologist about numbers
Oncologists are used to discussing benefit, but it helps to ask in a way that gets clear, personal answers rather than general trial summaries.
Ask for people out of a hundred
For example: out of a hundred people like me, how many would have a recurrence with hormone therapy alone, and how many with abemaciclib added?
Ask about time frames
Benefit figures are tied to a period, such as five years. Ask what the numbers mean over that time and beyond.
Bring someone with you
A family member can note the figures down, which helps when you think the decision over at home.
Commonly believed
What people assume about abemaciclib's benefit
A big relative reduction means a big personal benefit.
Absolute benefit depends on your starting risk.
If I take abemaciclib, the cancer will not come back.
It lowers the risk; it does not remove it.
A median means I have that long.
Half of people do better than the median, sometimes much better.
No survival data means no benefit.
Fewer recurrences are themselves meaningful, and survival data takes years.
Questions we are asked
Common questions about abemaciclib's benefit
Does abemaciclib help people live longer after surgery?
It clearly reduces recurrence, including spread to distant organs, which is closely linked with survival. Survival effects in early breast cancer take many years to measure fully. Ask your oncologist for the most recent overall survival update from the trial.
What does 'doubled the time before growth' mean?
It means the middle point at which half the people had their cancer grow was roughly twice as long with abemaciclib added. Some people had control for much longer, and some for shorter, than that middle point.
Is the benefit the same for everyone who takes it?
No. People with higher starting risk tend to gain more in absolute terms. The benefit also depends on your cancer's biology, your other health conditions and whether you are able to continue treatment.
Does it still work if my dose is reduced?
Analyses from the trials suggest people who needed dose reductions still appeared to gain benefit. These analyses have limitations, but they reassure many patients and doctors that a lower dose is a reasonable way to stay on treatment.
How does the benefit compare with chemotherapy?
They are used for different purposes and are not usually direct alternatives. Many high-risk patients have chemotherapy first and then abemaciclib with hormone therapy. Your oncologist can explain how each part contributes to lowering your risk.
Can I get a personal estimate of benefit?
Your oncologist can give a rough estimate based on your pathology, lymph nodes, grade and health. Online tools exist for early breast cancer, but they may not include abemaciclib or reflect every situation, so interpret them with your doctor.
Does the benefit continue after two years?
Follow-up of the trial after people finished abemaciclib has shown the gap in recurrence continuing and growing. This suggests the effect persists beyond the treatment period, although longer follow-up is still being reported.
Are the trial patients like me?
The trials included people from many countries, including Asian patients, but not every group was well represented. Your oncologist can judge how closely the evidence applies to your age, health and cancer.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Journal of Clinical Oncology — Abemaciclib combined with endocrine therapy for the adjuvant treatment of high-risk early breast cancer (monarchE)
- Journal of Clinical Oncology — MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
- National Cancer Institute — Abemaciclib
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.